Search research articles
Contact Us
Filters
Showing results (31-40 of 43) with videos related to
Page
of 5
Sort By:
International Journal of Endocrinology
|
April 18, 2015
Profiling of somatic mutations in phaeochromocytoma and paraganglioma by targeted next generation sequencing analysis
Andrea Luchetti, Diana Walsh, Fay Rodger, et al.
Global Change Biology. Bioenergy
|
August 23, 2016
Association mapping in <i>Salix viminalis</i> L. (Salicaceae) - identification of candidate genes associated with growth and phenology
Henrik R Hallingbäck, Johan Fogelqvist, Stephen J Powers, et al.
Current Medical Research and Opinion
|
October 22, 2022
Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma
Tom Martin, Saad Z Usmani, Jordan M Schecter, et al.
Current Medical Research and Opinion
|
July 14, 2021
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma
Tom Martin, Saad Z Usmani, Jordan M Schecter, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 28, 2022
Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
Katja Weisel, Amrita Krishnan, Jordan M Schecter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 13, 2011
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial
Paul G Richardson, Jeff Wolf, Andrzej Jakubowiak, et al.
BMC Research Notes
|
October 11, 2023
Genomic, transcriptomic and epigenomic sequencing data of the B-cell leukemia cell line REH
Mariya Lysenkova Wiklander, Elin Övernäs, Johanna Lagensjö, et al.
American Journal of Hematology
|
May 20, 2026
Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis
Murali Janakiram, Carlyn R Tan, Hira Mian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 2, 2019
Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline
Joseph Mikhael, Nofisat Ismaila, Matthew C Cheung, et al.
Biorxiv : the Preprint Server for Biology
|
January 30, 2023
Human Bone Marrow Plasma Cell Atlas: Maturation and Survival Pathways Unraveled by Single Cell Analyses
Meixue Duan, Doan C Nguyen, Chester J Joyner, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 43) with videos related to
Sort By:
Page
of 5
International Journal of Endocrinology
|
April 18, 2015
Profiling of somatic mutations in phaeochromocytoma and paraganglioma by targeted next generation sequencing analysis
Andrea Luchetti, Diana Walsh, Fay Rodger, et al.
Global Change Biology. Bioenergy
|
August 23, 2016
Association mapping in <i>Salix viminalis</i> L. (Salicaceae) - identification of candidate genes associated with growth and phenology
Henrik R Hallingbäck, Johan Fogelqvist, Stephen J Powers, et al.
Current Medical Research and Opinion
|
October 22, 2022
Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma
Tom Martin, Saad Z Usmani, Jordan M Schecter, et al.
Current Medical Research and Opinion
|
July 14, 2021
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma
Tom Martin, Saad Z Usmani, Jordan M Schecter, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 28, 2022
Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
Katja Weisel, Amrita Krishnan, Jordan M Schecter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 13, 2011
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial
Paul G Richardson, Jeff Wolf, Andrzej Jakubowiak, et al.
BMC Research Notes
|
October 11, 2023
Genomic, transcriptomic and epigenomic sequencing data of the B-cell leukemia cell line REH
Mariya Lysenkova Wiklander, Elin Övernäs, Johanna Lagensjö, et al.
American Journal of Hematology
|
May 20, 2026
Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis
Murali Janakiram, Carlyn R Tan, Hira Mian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 2, 2019
Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline
Joseph Mikhael, Nofisat Ismaila, Matthew C Cheung, et al.
Biorxiv : the Preprint Server for Biology
|
January 30, 2023
Human Bone Marrow Plasma Cell Atlas: Maturation and Survival Pathways Unraveled by Single Cell Analyses
Meixue Duan, Doan C Nguyen, Chester J Joyner, et al.
Page
of 5